Objective-Vascular smooth muscle cells (VSMC) from type 2 diabetic db/db mice exhibit enhanced proinflammatory responses implicated in accelerated vascular complications. We examined the role of microRNA(miR)-200 family members and their target Zeb1, an E-box binding transcriptional repressor, in these events. Methods and Results-The expression levels of miR-200b, miR-200c, and miR-429 were increased, although protein levels of Zeb1 were decreased in VSMC and aortas from db/db mice relative to control db/ϩ mice. Key Words: diabetes mellitus Ⅲ Zeb1 Ⅲ inflammatory genes Ⅲ miR-200 Ⅲ vascular complications P roinflammatory and proatherogenic responses in vascular smooth muscle cells (VSMC) play key roles in the development of atherosclerosis. 1-2 Diabetic conditions increase the expression of proinflammatory mediators such as receptor for advanced glycation end products, cyclooxygenase-2 (COX-2), cytokines such as tumor necrosis factor-␣ and interleukin-6, and chemokines such as monocyte chemoattractant protein-1 (MCP-1) and Fractalkine (CX3CL1) in VSMC and other inflammatory cells. 3-8 Inflammatory mediators promote proliferation, oxidant stress, migration, and monocyte-VSMC binding leading to VSMC dysfunction implicated in accelerated vascular complications of diabetes. 9 -10 Inflammatory gene expression is regulated by multiple signal transduction pathways leading to the activation of proinflammatory transcription factors such as nuclear factorkappaB (NF-B) and cAMP responsive element binding protein under diabetic conditions in VSMC. [3] [4] [5] 11 Recent studies have also demonstrated the role of epigenetic mechanisms, including histone posttranslational modifications, in the upregulation of inflammatory genes in endothelial cells and VSMC under diabetic conditions. 3,12,13 Enhanced expression of interleukin-6, MCP-1, and colony stimulating factor-1 in VSMC derived from type 2 diabetic db/db mice (db/ dbVSMC) was associated with reduced levels of the histone methyltransferase Suv39h1 and the corresponding repressive histone modification H3 lysine-9 trimethylation at their promoters, 12 suggesting that reversal of transcription repression could be a key mechanism for the enhanced expression of inflammatory genes in diabetes. In this study, we have uncovered a new cross talk mechanism between key miRNAs and their targets that further increases our understanding of molecular mechanisms involved in the derepression of pathological genes in VSMC under diabetic conditions. Zeb1 (also known as deltaEF1, TCF8, or Zfx1a) is a zinc finger transcription factor expressed in various cell types including VSMC. 14 It contains multiple functional domains including 2 zinc fingers, a centrally located homeodomain, and others that interact with various transcription regulators. Zeb1 binds to canonical E-box elements [CACCT(G)] in target gene promoters and mediates gene repression via interaction with corepressors including C-terminal-binding protein (CtBP) 1 (CtBP1), CtBP2, and HDAC1. Zeb1 and its 
P roinflammatory and proatherogenic responses in vascular smooth muscle cells (VSMC) play key roles in the development of atherosclerosis. [1] [2] Diabetic conditions increase the expression of proinflammatory mediators such as receptor for advanced glycation end products, cyclooxygenase-2 (COX-2), cytokines such as tumor necrosis factor-␣ and interleukin-6, and chemokines such as monocyte chemoattractant protein-1 (MCP-1) and Fractalkine (CX3CL1) in VSMC and other inflammatory cells. [3] [4] [5] [6] [7] [8] Inflammatory mediators promote proliferation, oxidant stress, migration, and monocyte-VSMC binding leading to VSMC dysfunction implicated in accelerated vascular complications of diabetes. 9 -10 Inflammatory gene expression is regulated by multiple signal transduction pathways leading to the activation of proinflammatory transcription factors such as nuclear factorkappaB (NF-B) and cAMP responsive element binding protein under diabetic conditions in VSMC. [3] [4] [5] 11 Recent studies have also demonstrated the role of epigenetic mechanisms, including histone posttranslational modifications, in the upregulation of inflammatory genes in endothelial cells and VSMC under diabetic conditions. 3, 12, 13 Enhanced expression of interleukin-6, MCP-1, and colony stimulating factor-1 in VSMC derived from type 2 diabetic db/db mice (db/ dbVSMC) was associated with reduced levels of the histone methyltransferase Suv39h1 and the corresponding repressive histone modification H3 lysine-9 trimethylation at their promoters, 12 suggesting that reversal of transcription repression could be a key mechanism for the enhanced expression of inflammatory genes in diabetes. In this study, we have uncovered a new cross talk mechanism between key miRNAs and their targets that further increases our understanding of molecular mechanisms involved in the derepression of pathological genes in VSMC under diabetic conditions. Zeb1 (also known as deltaEF1, TCF8, or Zfx1a) is a zinc finger transcription factor expressed in various cell types including VSMC. 14 It contains multiple functional domains including 2 zinc fingers, a centrally located homeodomain, and others that interact with various transcription regulators. Zeb1 binds to canonical E-box elements [CACCT(G)] in target gene promoters and mediates gene repression via interaction with corepressors including C-terminal-binding protein (CtBP) 1 (CtBP1), CtBP2, and HDAC1. Zeb1 and its family member Zeb2 (also known as SIP1 or Zfx1b) regulate genes associated with epithelial-mesenchymal transition (EMT), fibrogenesis, chrondrogenesis, T-cell development, skeletal muscle differentiation, pathogenesis of cancer, and renal complications such as diabetic nephropathy. 14 -17 However, the role of Zeb1 in inflammatory gene expression associated with diabetic vascular complications is not known.
Emerging evidence supports a role for microRNAs (miRNAs) in cardiovascular disease and diabetic complications. 13, 18, 19 miRNAs are 22 to 25 nucleotide noncoding RNAs that can repress target gene expression by posttranscriptional mechanisms. They act primarily through interaction with 3Ј-UTR of target mRNAs leading to downregulation or translation inhibition. 20 We recently showed that inhibition of Suv39h1 protein levels by miR-125b was one of the mechanisms underlying enhanced proinflammatory responses in db/dbVSMC. 21 However, the role of other miRNAs in these processes has not been examined. Lately, miR-200 family members have gained increased attention due to reports that they are downregulated in EMT implicated in cancer and metastasis. [22] [23] The miR-200 family consists of 5 members subdivided into Group I (miR-200a and miR-141) and Group II (miR-200b, miR200c, and miR-429). They share common targets because the seed sequence between the two groups differs only by a single nucleotide. In mice, miR-200b, miR-200a, and miR-429 are expressed as a single polycistronic transcript on chromosome 4 (chromosome 1 in humans), whereas miR-200c and miR-141 are expressed as a single transcript on chromosome 6 (chromosome 12 in humans). These miRNAs maintain epithelial cell phenotype by targeting transcription repressors Zeb1 and Zeb2 that repress E-cadherin. Zeb1/Zeb2 in turn negatively regulate miR-200 family members via E-box binding sites in their promoters. Dysregulation of this double negative feedback loop has been suggested to be a key mechanism in EMT and cancer. [22] [23] [24] On the other hand, recent studies showed that downregulation of Zeb1 and Zeb2 by increased miR-200 plays a key role in enhanced fibrotic gene expression in mesangial cells related to diabetic nephropathy. 16 However, this pathway has not been examined in gene expression related to cardiovascular diseases.
Here we examined the role of miR-200 and its target Zeb1 in the enhanced inflammatory responses of db/dbVSMC relative to VSMC from db/ϩ mice (db/ϩVSMC). Our results showed that miR-200b, miR-200c, and miR-429 levels are upregulated in db/dbVSMC leading to Zeb1 downregulation and enhanced inflammatory gene expression. miR-200 mimics directly targeted Zeb1 and promoted inflammatory responses in nondiabetic db/ϩVSMC. Furthermore, Zeb1 silencing also increased proinflammatory responses and expression of miR-200 members. Thus our studies identified novel proinflammatory effects associated with increased miR-200 and dysregulation of the reciprocal repression loop between Zeb1 and miR-200 in VSMC under diabetic conditions.
Materials and Methods
Expanded Materials and methods are available in the online-only Data Supplement.
VSMC Isolation
All animal protocols used were approved by the Institutional Animal Use and Care Committee. VSMC from thoracic aortas of Type 2 diabetic male db/db mice (10 -12 weeks old) and age matched control littermates db/ϩ mice (Jackson Laboratories) were isolated by enzymatic digestion 4 and cultured in DMEM/F12 medium supplemented with 10% fetal bovine serum. HeLa cells were cultured in DMEM supplemented with 10% serum.
Other Methods
Western blotting, analyses of miRNA and mRNA by reverse transcriptase-real time quantitative PCR (RT-QPCR), transient transfections, luciferase assays, immunohistochemical staining, and monocyte-VSMC binding assays were performed as described in the online-only Data Supplement.
Chromatin Immunoprecipitation Assays
Chromatin immunoprecipitation (ChIP) assays were performed as described in the online-only Data Supplement. ChIP-enriched DNA was amplified by SYBR green based QPCR using promoter specific primers (Table I in the online-only Data Supplement), analyzed by 2
Ϫ⌬⌬Ct method and results normalized to input were expressed as % of db/ϩVSMC. 12 
Statistical Analysis
Statistical significance was calculated with Prism software (Graphpad, San Diego, CA) by t-tests when comparing 2 groups, or ANOVA for multiple groups. Data were presented as meansϮSEM.
Results

Levels of Key miR-200 Family Members Are Increased in VSMC and Aortas From db/db Mice
To examine the functional role of miR-200 family members in db/dbVSMC, we first determined their expression levels by RT-QPCR analysis. Results showed that miR-200b, miR-429, and miR-200c levels were significantly increased in db/ dbVSMC compared to db/ϩVSMC ( Figure 1A-C) . On the other hand, miR-200a that is cotranscribed along with miR200b/429 was not detected in either db/ϩ or db/dbVSMC (not shown). Levels of miR-15b, unrelated to the miR-200 family, were not changed ( Figure 1D ), indicating specificity. Expression of miR-200b and miR-429 was also significantly increased in aortas derived from db/db mice relative to db/ϩ mice ( Figure 1E and 1F) establishing in vivo relevance.
Zeb1 Levels Are Decreased in VSMC and Aortas From db/db Mice
Zeb1 3Ј-UTR contains multiple miR-200 binding sites (Figure I in the online-only Data Supplement). Studies in other cell types showed that miR-200 family members target E-box binding transcription repressor Zeb1 and modulate genes associated with cancer and diabetic nephropathy. 16, [22] [23] However, this inverse relationship has not been studied in VSMC and whether it can modulate processes associated with vascular complications has not been determined. We first examined whether the increased miR-200b and miR-429 noted in db/db mice was associated with downregulation of Zeb1 levels. Immunohistochemical staining with Zeb1 antibody revealed a significant decrease in Zeb1 positive nuclei in VSMC of aortas derived from db/db mice compared to db/ϩ ( Figure 1G and 1H) . Furthermore, immunoblotting of cell lysates showed that Zeb1 protein levels were significantly reduced in VSMC cultured from db/db mice compared to db/ϩ mice ( Figure 1I and 1J) . These results clearly demonstrated that Zeb1 expression is downregulated in VSMC of diabetic mice and established the reciprocal relation with increased miR-200 expression.
Zeb1 Downregulation by miR-200b and miR-429
We next tested if Zeb1 is a direct target of these miRNAs in VSMC. We transfected nondiabetic db/ϩVSMC with miR- Figure 2D) . These results clearly demonstrate that Zeb1 is a direct target of miR-200b and miR-429 in VSMC, and that increased levels of these miRNAs could be a mechanism for downregulation of Zeb1 in db/dbVSMC.
Upregulation of Inflammatory Genes by miR-200b and miR-429
Because we noted the presence of E-boxes in the promoters of some inflammatory genes such as COX-2 that are upregulated in db/dbVSMC, we next hypothesized that loss of Zeb1 might be a mechanism for derepression of these genes. We therefore examined the potential functional roles of miR200b and miR-429 in VSMC by transfecting db/ϩVSMC with NC-M and 200b-M or 429-M oligonucleotides. Inflammatory gene expression was analyzed 48 hours post transfection. Results showed that Zeb1 mRNA expression was downregulated whereas levels of COX-2 and MCP-1 mRNAs were significantly upregulated in db/ϩVSMC transfected with 200b-M compared to NC-M ( Figure 2E ). However, 200b-M had no effect on other inflammatory genes such as CX3CL1 and receptor for advanced glycation end products that were also upregulated in db/dbVSMC (data not shown). Transfection of 429-M also inhibited Zeb1 and increased COX-2 and MCP-1 in db/ϩVSMC ( Figure 2F ). Next, we examined whether miR-200b regulates the transcriptional activation of inflammatory gene promoters. COX-2 promoter contains cis-elements such as E-box, cyclic-AMP response element and NF-B upstream of transcription start site ( Figure 2G ). We used plasmids containing luciferase reporter downstream of COX-2 wild type (WT) promoter or promoter with mutations in these binding sites 25 to determine if miR-200 affects their transcriptional activation. Cotransfection experiments showed that 200b-M significantly increased the luciferase activity of COX-2 WT promoter compared to NC-M, but failed to activate COX-2 promoter constructs with mutations in E-box, NF-B (KBm) or cyclic-AMP response element (CREm) binding sites ( Figure 2H ) suggesting potential crosstalk between these 3 sites examined. These results demonstrate that miR-200 family has proinflammatory roles in VSMC and that downregulation of Zeb1 could be a key mechanism involved, at least in part. Images were collected using an Olympus BX51 microscope and Zeb1 positive nuclei per field counted using Adobe Photoshop program (*PϽ0.05 vs db/ϩ, nϭ3). I, J, Zeb1 protein levels in cell lysates from db/ϩVSMC (db/ϩ) and db/dbVSMC (db/db) were determined by immunoblotting with Zeb1 antibodies (I), and Zeb1 protein levels normalized with ␤-actin protein were expressed as % of db/ϩ (**, PϽ0.005 vs db/ϩ, nϭ9).
Zeb1 Gene Silencing Upregulates Inflammatory Genes in db/؉VSMC
To examine the direct role of Zeb1 in inflammatory gene expression, we transfected db/ϩVSMC with 2 siRNAs targeting Zeb1 (siZeb1a and siZeb1b) or a nontargeting control (siNTC) oligonucleotides. Zeb1 siRNAs significantly inhibited Zeb1 mRNA levels ( Figure 3A) and also increased the expression of COX-2 ( Figure 3B ) and MCP-1 ( Figure 3C ) compared to siNTC. However, the expression of receptor for advanced glycation end products and another chemokine CX3CL1, which were shown to be upregulated in db/dbVSMC, 6, 26 was not affected (data not shown). Furthermore, cotransfection of COX-2 WT promoter luciferase reporter plasmid with siZeb1 (1:1 mixture of siZeb1a and siZeb1b) significantly increased COX-2 WT (WT) promoter activity relative to siNTC ( Figure  3D ). Furthermore, COX-2 E-box mutant promoter activity was elevated relative to WT promoter in siNTC transfected cells, and this was further increased by siZeb1 ( Figure 3D ). These results demonstrate that Zeb1 can repress these inflammatory genes in VSMC under normal conditions and that its downregulation in diabetes (via miR-200) can relieve this repression to augment expression.
Zeb1 Binding to Inflammatory Gene Promoters is Reduced in db/dbVSMC
In order to further verify that a loss of Zeb1 at the MCP-1 and COX-2 promoters is associated with the increased expression of these genes in diabetic db/dbVSMC, we next used ChIP assays to examine Zeb1 occupancy at these promoters. ChIP assays were performed with Zeb1 antibody, and ChIP DNA analyzed by QPCR with promoter specific primers ( Figure III in the online-only Data Supplement). Results showed that Zeb1 occupancy was significantly reduced at both COX-2 ( Figure 3E ) and MCP-1 promoters ( Figure 3F ), with no significant change at the Cyclophilin A promoter ( Figure 3G ) in db/dbVSMC compared to db/ϩVSMC. Because transfection of 200b-M downregulates Zeb1 and increases inflammatory gene expression which mimics the proinflammatory db/db phenotype, we examined if it also leads to reduced Zeb1 occupancy at inflammatory gene promoters. We performed ChIP assays with cell lysates from NC-M and 200b-M transfected db/ϩVSMC using Zeb1 antibody. Results showed that Zeb1 occupancy was greatly reduced at COX-2 and MCP-1 gene promoters in 200b-M transfected cells demonstrating that 200b-M effects can be mediated through Zeb1 downregulation ( Figure 3H ). These results further support our hypothesis that enhanced expression of key VSMC inflammatory genes in diabetes could be due to reduced Zeb1 occupancy at their promoters.
COX-2 Plays a Role in Enhanced Monocyte Binding in db/dbVSMC
Next we examined the functional relevance of miR-200b and Zeb1 mediated gene expression in proinflammatory responses such as monocyte-VSMC binding. Previous studies showed the role of MCP-1 in enhanced monocyte binding in db/dbVSMC relative to control db/ϩVSMC. 4, 6 However, the involvement of increased COX-2 was not studied. We first confirmed that COX-2 mRNA ( Figure 4A ) and protein (Figure 4B and 4C) levels were significantly increased in db/dbVSMC relative to db/ϩVSMC. Then, both db/ϩVSMC and db/db-VSMC were pretreated with COX-2 specific inhibitor Celecoxib (1 and 10 mol/L) or the vehicle DMSO (control) for 1 hour. Monocyte-VSMC binding assays were performed with fluorescently labeled mouse WEHI monocytes. Results showed that vehicle treated db/dbVSMC exhibited significantly enhanced monocyte binding compared to db/ϩVSMC, and this was blocked by pretreatment with Celecoxib ( Figure 4D and 4E ). These results demonstrate a key role for COX-2 in the enhanced monocyte binding displayed by the diabetic db/dbVSMC relative to control db/ϩVSMC. or an E-box mutant promoter (EBm) were cotransfected with siNTC, and siZeb1 oligonucleotides into db/ϩVSMC and luciferase assays performed 72 hours posttransfection. Relative luciferase activity normalized with Renilla luciferase was expressed as fold over siNTC (*PϽ0.05, ***PϽ0.0002, nϭ8). E-G, Zeb1 occupancy at inflammatory gene promoters was analyzed by chromatin immunoprecipitation (ChIP) assays with db/ϩ and db/dbVSMC cell lysates using Zeb1 antibodies. ChIP enriched DNA was analyzed by QPCR using indicated promoter primers (Location of primers is shown in 
Regulation of Monocyte-VSMC Binding by miR-200b in Diabetes
To Figure 5A and 5B). Next, we tested if the enhanced monocyte binding in diabetic db/dbVSMC can be blocked by miR-200b inhibitors. We transfected db/dbVSMC with miR200b inhibitor (200b-I) that targets miR-200b hairpin, or negative control inhibitor (NC-I) oligonucleotides. In addition, db/ϩVSMC were also transfected with NC-I as a control for db/dbVSMC. Results showed that db/dbVSMC transfected with NC-I exhibited enhanced monocyte binding compared to db/ϩVSMC transfected with NC-I ( Figure 5C ). Furthermore, transfection of db/dbVSMC with 200b-I significantly attenuated this enhanced monocyte binding, thus reversing the proinflammatory phenotype ( Figure 5C ). These results demonstrate that increased miR-200b can promote, at least in part, the inflammatory responses in VSMC under diabetic conditions.
Zeb1 Knockdown Increases Monocyte-VSMC Binding in db/؉VSMC
Since Zeb1 also negatively regulates COX-2 and MCP-1, we studied the direct effect of Zeb1 knockdown on monocyte-VSMC binding. As shown in Figure 6A and 6B, transfection of siZeb1a or siZeb1b significantly increased monocyte-VSMC binding relative to siNTC confirming that Zeb1 is an endogenous repressor of key genes such as MCP-1 and COX-2 involved in VSMC-monocyte interactions.
Zeb1 Knockdown Upregulates miR-200b and miR-429
Studies in epithelial cells showed that Zeb1 can also negatively regulate miR-200 expression. 23 Figure 6D ) and miR-429 ( Figure 6E ) levels in db/ϩVSMC but had no effect on miR-21 levels ( Figure 6F ). These results demonstrate that Zeb1-and miR-200 cross talk and regulate each other through a double negative feedback loop in VSMC ( Figure 6G ).
Discussion
In this study, we demonstrated that miR- 27 and streptozotocin induced diabetic retinopathy 28 increased the expression of its targets Ets-1 and VEGF that promote angiogenesis. In contrast, increased levels of miR-200b and miR-200c were seen in diabetic mouse glomeruli 16, 29 and in renal mesangial cells treated with TGF-␤, resulting in Zeb1 and Zeb2 downregulation and increased fibrotic gene expression, 16 a key mechanism involved in diabetic nephropathy. Our results demonstrate that increased levels of miR-200b, miR-200c and miR-429 are present in VSMC of type 2 diabetic mice along with Zeb1 downregulation and enhanced inflammatory gene expression. These studies reveal the cell and disease-specific differences and complexities in the regulation of miR-200 family members, as well as the diverse roles played by them in various pathophysiological conditions.
Inflammatory genes are regulated by transcription factors such as NF-B and cAMP responsive element binding protein in VSMC, and activities of these are enhanced under diabetic conditions. [3] [4] [5] 13 We found that COX-2 promoter activation by miR-200b required cis-elements NF-B and cyclic-AMP response element suggesting its interaction with pathways involved in the activation of NF-B and cAMP responsive element binding protein in VSMC. Furthermore, mutations in E-box increased the basal activity of the COX-2 promoter demonstrating that binding of repressors such as Zeb1 might inhibit its activity. However, miR-200b did not further enhance E-box mutant activity suggesting that E-box element in COX-2 promoter binds to both positive and negative regulatory transcription factors. Indeed, studies in other cell types showed that transcription factors USF-1 and USF-2 activate COX-2 promoter through binding to this E-box. 30 -31 This suggests that any alterations in the fine balance between activating and repressive transcription factors at promoters of pathological genes might be one of mechanisms underlying enhanced inflammatory gene expression mediated by miR-200b in VSMC.
Zeb1 gene silencing (by siRNAs) also increased inflammatory genes and increased COX-2 WT promoter activation in VSMC. In addition, E-box mutant COX-2 promoter showed increased activity relative to WT in siNTC transfected cells, which was further enhanced by Zeb1 knockdown, demonstrating negative regulatory role of Zeb1 and E-box elements in VSMC. Furthermore, ChIP assays demonstrated reduced Zeb1 occupancy at both COX-2 and MCP-1 promoter in db/dbVSMC and in db/ϩVSMC transfected with 200b-M, further supporting the notion that Zeb1 inhibition can contribute to the enhanced inflammatory gene expression in db/dbVSMC. Interestingly, the MCP-1 proximal promoter region amplified in Zeb1 ChIP assays did not have a canonical E-box element, yet Zeb1 knockdown increased MCP-1 expression. This suggests that the MCP-1 promoter may have unidentified putative Zeb1 binding sites in its proximal promoter or away from the promoter. Previous studies have shown that Zeb1 binding as far as 16 kb away from transcription start site can influence Col1a2 gene expression. 1532 Alternately, Zeb1 may interact with the MCP-1 promoter indirectly through protein-protein interactions with transcription repressors such as CtBP1 and CtBP2. 33 Furthermore, Zeb1 can associate with repressor complexes formed by CtBP at gene promoters, which also includes other transcription repressors such as histone deacetylase 1 and lysine specific demethylase 1, a histone H3 lysine 4 demethylase. 14,34 -35 In addition, increases in miR-200 levels in Zeb1 knockdown VSMC ( Figure 6D and 6E) can further amplify inflammatory gene expression. Overall, our results suggest that Zeb1 can exert repressive effects at inflammatory gene promoters through multiple mechanisms in VSMC.
Evidence shows that Zeb1 negatively regulates the expression of miR-200 members through binding to E-box elements located upstream of their promoters in epithelial cells, whereas miR-200 in turn downregulates Zeb1 through 3Ј-UTR inhibition. 23 This reciprocal negative regulatory loop has been implicated in pathological conditions including EMT, [22] [23] [24] renal fibrosis and diabetic nephropathy. [15] [16] [17] 19 Our current studies demonstrate the operation of this reciprocal regulation and a novel proinflammatory function for miR-200 family members in VSMC. In contrast, Zeb1 knockdown by siRNAs or miR-200 transfection alone did not increase ECM genes such as Col1a2 and Col4a1 expression in VSMC (not shown) suggesting the requirement of additional transcription factors as shown previously in VSMC 32 and MC. 16 Thus, a balance between Zeb1 and miR-200 members seems to regulate or fine tune the expression of inflammatory genes in VSMC while a dysregulation of this balance under diabetic conditions leads to inappropriate expression ( Figure 6G ). However, from these studies it is not clear how Zeb1 and miR-200b expression is regulated in the diabetic state. Exposure of VSMC to high glucose (25 mmol/L) alone did not alter miR-200 and Zeb1 levels in VSMC (data not shown). This is in contrast to miR-200b downregulation by high glucose in human umbilical vein ECs and bovine retinal capillary ECs, mimicking miR-200b downregulation in retinas from streptozotocin induced diabetic rats, 28 further suggesting cell and tissue specific differences in miRNA regulation. The observed changes in miRNAs in diabetic db/ dbVSMC could be a cumulative effect of hyperglycemia, dyslipidemia, hyperinsulinemia, and insulin resistance associated with this Type 2 diabetes model. Furthermore, diabetes activates multiple signaling pathways including oxidant stress, protein kinase C, tyrosine kinases, MAPKs, and AGEs, 3, 5, 11 many of which are altered in this model. 4, 6, 26 Involvement of these and other potential mechanisms including increased expression of growth factors such as TGF-␤ 16 and PDGF-D 36 in disrupting the miR-200-Zeb1 loop in VSMC awaits further investigation.
Inflammatory genes in VSMC play key roles in the development of vascular complications by promoting VSMC migration, proliferation, and monocyte binding. Previous results from in vitro and ex vivo studies showed that MCP-1 and CX3CL1, which are increased under diabetic conditions, mediate enhanced monocyte-VSMC binding and foam cell formation, key events in the pathogenesis of atherosclerosis. 4, 6 Thus, miR-200 -Zeb1 regulation of inflammatory genes such as MCP-1 and COX-2 could promote monocyte binding and subsequent differentiation in the subendothelial space and thereby contribute to accelerated vascular complications. Reports show that elevated COX-2 in db/dbVSMC was also associated with vascular smooth muscle hypercontractility related to hypertension. 37, 38 Therefore, miR-200 mediated COX-2 expression might also be involved in accelerated hypertension associated with diabetes.
In summary, we have identified a novel proinflammatory role for the negative feedback loop between miR-200 and Zeb1 in VSMC. Our previous studies showed the role of miR-125b in promoting inflammatory gene expression through downregulation of the epigenetic repressive histone methyltransferase Suv39h1 in db/dbVSMC. 21 Together, these studies suggest that miRNA mediated targeting and downregulation of repressive mechanisms regulated by key epigenetic and transcription factors might augment proinflammatory responses of VSMC. These results could lead to the identification of potential new therapeutic targets for the accelerated vascular complications in diabetes.
